The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma
The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU drug licensing body) Committee for Medicinal Products for Human Use (CHMP), after which the European Commission had 60 days to ratify. The decision means that the product is safe and effective to prescribe in myeloma patients in the 27 EU…